Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 385-388, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-357416
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of cetuximab in combination with chemotherapy for gastrointestinal cancers.</p><p><b>METHODS</b>The data of 35 colorectal cancers (CRC), 11 advanced gastric cancers (AGC) and 3 other gastrointestinal cancers treated with cetuximab in combination with chemotherapy were retrospectively reviewed, and the efficacy and adverse events were analyzed.</p><p><b>RESULTS</b>Of the 49 patients, 37 were evaluable. Twenty-nine CRC were evaluated by RECIST criteria with a PR rate of 24.1%, SD rate of 51.8% and disease control rate (DC) of 75.9%. Subgroup analysis showed that the response rate (RR) and DC rate were 36.4% and 90.9% for the first-line therapy, 20.0% and 70.0% for the second-line therapy, 12.5% and 62.5% in the heavily pre-treated cases, respectively. Six patients with AGC were assessed for efficacy, including 2 PR for first-line therapy, 1 CR and 1 SD for second-line therapy, and 2 with progressive disease in the heavily pre-treated cases. Rash was observed in 79.6% of the patients with a grade 3 rate of 8.2%, and the severity was relevant to the DC. Grade 3 or 4 neutropenia was observed in 16.3%, and grade 3 infusion related reaction (IRR) happened in 4.1% (2 cases).</p><p><b>CONCLUSION</b>Cetuximab combined with chemotherapy is safe and effective for patients with gastrointestinal cancer. In colorectal cancers, the combination therapy shows a high disease control rate, especially in first-line therapy. The severity of rash may be parallel with efficacy. The combination therapy is also promising in the treatment of AGC.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Gástricas
/
Inducción de Remisión
/
Neoplasias Colorrectales
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Estudios Retrospectivos
/
Estudios de Seguimiento
/
Terapia Combinada
/
Usos Terapéuticos
/
Quimioterapia
/
Exantema
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS